It was found that, when treated with DCLK1 inhibitor, the elevated levels of β‐catenin in nucleus, CCAR1 and DCLK1 in DCLK1‐overexpressing CRC cells were dramatically attenuated (Figure 8A). Here, DCLK1 is linked to colorectal carcinoma.